Insmed, Inc. (INSM) vs Moderna, Inc. (MRNA)
Insmed, Inc. and Moderna, Inc. are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $78.8B against $26.8B — 2.9× the size. Insmed, Inc. grew revenue faster over the last twelve months: 185.8% against −27.6%. Insmed, Inc. has the higher net margin (−76.9% vs −141.4%) and the lower return on invested capital (−329.2% vs −93.5%). Across the 18 metrics below, Insmed, Inc. leads on 10 and Moderna, Inc. on 8.
Valuation
Profitability
| Metric | INSM | MRNA | Biotechnology median |
|---|---|---|---|
| Gross margin | 83.46% | 23.38% | 65.16% |
| Operating margin | (73.89%) | (149.01%) | 0.00% |
| Net margin | (76.94%) | (141.43%) | 0.00% |
| Free cash flow margin | (71.00%) | (55.83%) | 0.00% |
| Return on equity | (87.22%) | (39.00%) | (57.72%) |
| Return on assets | (38.20%) | (27.43%) | (49.22%) |
| Return on invested capital | (329.22%) | (93.47%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack